Mustang Bio Launches CRISPR/Cas9 CAR-T Collaborations with Harvard, BIDMC

Mustang Bio said today it plans to develop CRISPR/Cas9 -enhanced chimeric antigen receptor engineered T-cell (CAR-T) therapies for cancer through a license from Harvard University and a research collaboration agreement with Beth Israel Deaconess Medical Center (BIDMC).The value of both agreements was not disclosed. CRISPR stands for clustered regularly interspaced short palindromic repeats.Mustang Bio, a subsidiary of Fortress Biotech, said that technologies related to the development of off-the